R&D Closed and Collaborative: Mergers, acquisitions, and partner... As we head further into H2, a final look back to the summer’s industry mergers and acquisiti
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Welcome to a new pharmaphorum round-up.
News Merck, Allergan named as potential bidders for Biogen Biogen vulnerable to takeover as chief executive steps down
News Medivation hits back at Sanofi's boardroom coup attempt Sanofi has unveiled plans to replace the entire board of Medivation in order to push through its $9.3 billion takeover bid.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face